Rubius Therapeutics Inc (NASDAQ:RUBY) – Stock analysts at Jefferies Financial Group issued their Q1 2019 earnings per share estimates for shares of Rubius Therapeutics in a report issued on Tuesday, November 13th. Jefferies Financial Group analyst M. Yee anticipates that the company will post earnings per share of ($0.50) for the quarter. Jefferies Financial Group currently has a “Buy” rating and a $40.00 price target on the stock. Jefferies Financial Group also issued estimates for Rubius Therapeutics’ Q2 2019 earnings at ($0.53) EPS, Q3 2019 earnings at ($0.57) EPS and Q4 2019 earnings at ($0.61) EPS.

A number of other equities research analysts have also recently commented on RUBY. JPMorgan Chase & Co. initiated coverage on Rubius Therapeutics in a research note on Monday, August 13th. They issued an “overweight” rating on the stock. Morgan Stanley initiated coverage on Rubius Therapeutics in a research note on Monday, August 13th. They issued an “overweight” rating and a $37.00 target price on the stock. Leerink Swann initiated coverage on Rubius Therapeutics in a research note on Monday, August 13th. They issued an “outperform” rating on the stock. Finally, Zacks Investment Research cut Rubius Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 1st. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $38.50.

NASDAQ RUBY opened at $20.35 on Thursday. Rubius Therapeutics has a 12 month low of $14.50 and a 12 month high of $33.01.

Rubius Therapeutics (NASDAQ:RUBY) last released its earnings results on Tuesday, November 13th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.06).

Several institutional investors have recently added to or reduced their stakes in the stock. MetLife Investment Advisors LLC purchased a new stake in shares of Rubius Therapeutics during the third quarter valued at $405,000. Zimmer Partners LP purchased a new stake in shares of Rubius Therapeutics during the third quarter valued at $360,000. EcoR1 Capital LLC purchased a new stake in shares of Rubius Therapeutics during the third quarter valued at $14,211,000. Capital World Investors purchased a new stake in shares of Rubius Therapeutics during the third quarter valued at $67,869,000. Finally, Capital International Investors purchased a new stake in shares of Rubius Therapeutics during the third quarter valued at $12,525,000. 0.01% of the stock is currently owned by institutional investors.

About Rubius Therapeutics

Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.

Featured Article: Asset Allocation Models, Which is Right For You?

Earnings History and Estimates for Rubius Therapeutics (NASDAQ:RUBY)

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.